XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
6 Months Ended
Jul. 03, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 11. Fair Value Measurements
Recurring Fair Value Measurements
The assets and liabilities carried at fair value, measured on a recurring basis, as of July 3, 2021 were as follows:
 
           
Fair Value Measurements Using
 
(In millions)   
            Total
    
   Quoted Prices
in Active
Markets
(Level 1)
    
Significant
Other
   Observable
Inputs
(Level 2)
    
Significant
Other
   Unobservable
Inputs
(Level 3)
 
Assets
                                   
Investments
   $ 33.9      $ 27.0      $ 6.9      $  
Derivative assets
     9.3       
.6
       8.7         
Bank drafts
     12.4        12.4                
Liabilities
                                   
Cross-currency swap
   $ 25.2      $      $ 25.2      $  
Derivative liabilities
     5.8               5.8         
Contingent consideration liabilities
     10.4                      10.4  
The assets and liabilities carried at fair value, measured on a recurring basis, as of January 2, 2021 were as follows:
 
           
Fair Value Measurements Using
 
(In millions)   
            Total
    
   Quoted Prices
in Active
Markets
(Level 1)
    
Significant
Other
   Observable
Inputs
(Level 2)
    
Significant
Other
   Unobservable
Inputs
(Level 3)
 
Assets
                                   
Investments
   $ 33.6      $ 27.4      $ 6.2      $  
Derivative assets
     5.2        .1        5.1         
Bank drafts
     12.8        12.8                
Liabilities
                                   
Cross-currency swap
   $ 36.7      $      $ 36.7      $  
Derivative liabilities
     9.5        .3        9.2         
Investments include fixed income securities (primarily U.S. government and corporate debt securities) measured at fair value using quoted prices/bids and a money market fund measured at fair value using net asset value. As of July 3, 2021, investments of $.8 million and $33.1 million were included in “Cash and cash equivalents” and “Other current assets,” respectively, in the unaudited Condensed Consolidated Balance Sheets. As of January 2, 2021, investments of $1 million and $32.6 million were included in “Cash and cash equivalents” and “Other current assets,” respectively, in the unaudited Condensed Consolidated Balance Sheets. Derivatives that are exchange-traded are measured at fair value using quoted market prices and classified within Level 1 of the valuation hierarchy. Derivatives measured based on foreign exchange rate inputs that are readily available in public markets are classified within Level 2 of the valuation hierarchy. Bank drafts (maturities greater than three months) are valued at face value due to their short-term nature and were included in “Other current assets” in the unaudited Condensed Consolidated Balance Sheets.
Contingent consideration liabilities relate to estimated earn-out payments associated with one of the 2021 Acquisitions. These payments are based on the achievement of certain performance targets based on the terms of the purchase agreement, and our estimates are based on the expected payments related to these targets as of July 3, 2021. 
We have classified these liabilities as Level 3. As of July 3, 2021, contingent consideration liabilities of approximately $3 million and $7 million were included in “Other current liabilities” and “Long-term retirement benefits and other liabilities,” respectively, in the unaudited Condensed Consolidated Balance Sheets.
Avery Dennison Corporation
 
T
he activity related to contingent consideration for the six months ended July 3, 2021 is shown below.
 
(In millions)
  
  
 
Acquisition
  
$
11.6
 
Payments
  
 
(1.2
Balance at July 3, 2021
  
$
                    10.4